420 reports of this reaction
2.1% of all ASENAPINE MALEATE reports
#10 most reported adverse reaction
ANOSOGNOSIA is the #10 most commonly reported adverse reaction for ASENAPINE MALEATE, manufactured by Allergan, Inc.. There are 420 FDA adverse event reports linking ASENAPINE MALEATE to ANOSOGNOSIA. This represents approximately 2.1% of all 20,068 adverse event reports for this drug.
Patients taking ASENAPINE MALEATE who experience anosognosia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANOSOGNOSIA is a less commonly reported adverse event for ASENAPINE MALEATE, but still significant enough to appear in the safety profile.
In addition to anosognosia, the following adverse reactions have been reported for ASENAPINE MALEATE:
The following drugs have also been linked to anosognosia in FDA adverse event reports:
ANOSOGNOSIA has been reported as an adverse event in 420 FDA reports for ASENAPINE MALEATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANOSOGNOSIA accounts for approximately 2.1% of all adverse event reports for ASENAPINE MALEATE, making it a notable side effect.
If you experience anosognosia while taking ASENAPINE MALEATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.